Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.

Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW.

Sci Transl Med. 2012 Aug 8;4(146):146ra107. doi: 10.1126/scitranslmed.3004241.

2.

A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF.

Antiviral Res. 2013 Oct;100(1):8-13. doi: 10.1016/j.antiviral.2013.06.012. Review.

3.

Immunization strategies against henipaviruses.

Broder CC, Geisbert TW, Xu K, Nikolov DB, Wang LF, Middleton D, Pallister J, Bossart KN.

Curr Top Microbiol Immunol. 2012;359:197-223. doi: 10.1007/82_2012_213. Review.

4.

Animal challenge models of henipavirus infection and pathogenesis.

Geisbert TW, Feldmann H, Broder CC.

Curr Top Microbiol Immunol. 2012;359:153-77. doi: 10.1007/82_2012_208. Review.

PMID:
22476556
5.

Pathogenesis of Hendra and Nipah virus infection in humans.

Escaffre O, Borisevich V, Rockx B.

J Infect Dev Ctries. 2013 Apr 17;7(4):308-11. doi: 10.3855/jidc.3648. Review.

6.

Developments towards effective treatments for Nipah and Hendra virus infection.

Bossart KN, Broder CC.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):43-55. Review.

PMID:
16441208
7.

Hendra and Nipah viruses: pathogenesis and therapeutics.

Eaton BT, Broder CC, Wang LF.

Curr Mol Med. 2005 Dec;5(8):805-16. Review.

PMID:
16375714
8.

Hendra and Nipah viruses: different and dangerous.

Eaton BT, Broder CC, Middleton D, Wang LF.

Nat Rev Microbiol. 2006 Jan;4(1):23-35. Review.

PMID:
16357858
9.

Henipavirus pathogenesis and antiviral approaches.

Mathieu C, Horvat B.

Expert Rev Anti Infect Ther. 2015 Mar;13(3):343-54. doi: 10.1586/14787210.2015.1001838. Review.

PMID:
25634624
10.

[Study of pathogenicity of Nipah virus and its vaccine development].

Yoneda M.

Uirusu. 2014;64(1):105-12. doi: 10.2222/jsv.64.105. Review. Japanese.

11.

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS.

Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755 . Review. Erratum in: Expert Opin Biol Ther. 2009 Apr;9(4):533.

12.

Henipavirus Encephalitis: Recent Developments and Advances.

Ong KC, Wong KT.

Brain Pathol. 2015 Sep;25(5):605-13. doi: 10.1111/bpa.12278. Review.

PMID:
26276024
13.

Nipah and hendra virus interactions with the innate immune system.

Basler CF.

Curr Top Microbiol Immunol. 2012;359:123-52. doi: 10.1007/82_2012_209. Review.

PMID:
22491899
14.

Hendra and nipah infection: pathology, models and potential therapies.

Vigant F, Lee B.

Infect Disord Drug Targets. 2011 Jun;11(3):315-36. Review.

15.

Envelope-receptor interactions in Nipah virus pathobiology.

Lee B.

Ann N Y Acad Sci. 2007 Apr;1102:51-65. Review.

PMID:
17470911
16.

Hendra and Nipah viruses: why are they so deadly?

Marsh GA, Wang LF.

Curr Opin Virol. 2012 Jun;2(3):242-7. doi: 10.1016/j.coviro.2012.03.006. Review.

PMID:
22483665
17.

Henipavirus: a review of laboratory animal pathology.

Williamson MM, Torres-Velez FJ.

Vet Pathol. 2010 Sep;47(5):871-80. doi: 10.1177/0300985810378648. Review.

18.

Emerging tropical diseases in Australia. Part 5. Hendra virus.

Tulsiani SM, Graham GC, Moore PR, Jansen CC, Van Den Hurk AF, Moore FA, Simmons RJ, Craig SB.

Ann Trop Med Parasitol. 2011 Jan;105(1):1-11. doi: 10.1179/136485911X12899838413547. Review.

19.

The changing face of the henipaviruses.

Croser EL, Marsh GA.

Vet Microbiol. 2013 Nov 29;167(1-2):151-8. doi: 10.1016/j.vetmic.2013.08.002. Review.

PMID:
23993256
20.

Molecular characteristics of the Nipah virus glycoproteins.

Diederich S, Maisner A.

Ann N Y Acad Sci. 2007 Apr;1102:39-50. Review.

PMID:
17470910
Items per page

Supplemental Content

Support Center